Difference between revisions of "Cerebrospinal fluid"
(Created page with "'''Dementia''' CSF biomarkers for Alzheimer’s disease demonstrate characteristic low amyloid-β1-42 (Aβ42) and high total and phosphorylated tau (p-tau) levels. 166 When...") |
|||
| Line 1: | Line 1: | ||
'''Dementia''' | '''Dementia''' | ||
| − | CSF biomarkers for Alzheimer’s disease demonstrate characteristic low amyloid-β1-42 (Aβ42) and high total and phosphorylated tau (p-tau) levels | + | CSF biomarkers for Alzheimer’s disease demonstrate characteristic low amyloid-β1-42 (Aβ42) and high total and phosphorylated tau (p-tau) levels (Mattsson et al, 2009) |
| − | When predicting if MCI would develop incipient AD: | + | When predicting if MCI would develop incipient AD: (Mattsson et al, 2009) |
* Aβ42 ≤482ng/L | * Aβ42 ≤482ng/L | ||
| − | ** Sensitivity: 79% | + | ** Sensitivity: 79%; Specificity: 65%; Positive likelihood ratio: 2.3; Negative likelihood ratio: 0.32 |
| − | |||
| − | |||
| − | |||
* T-tau ≥320ng/L | * T-tau ≥320ng/L | ||
| − | ** Sensitivity: 86% | + | ** Sensitivity: 86%; Specificity: 56%; Positive likelihood ratio: 1.9; Negative likelihood ratio: 0.26 |
| − | |||
| − | |||
| − | |||
* P-tau ≥52ng/L | * P-tau ≥52ng/L | ||
| − | ** Sensitivity: 84% | + | ** Sensitivity: 84%; Specificity: 47%; Positive likelihood ratio: 1.6; Negative likelihood ratio: 0.34 |
| − | |||
| − | |||
| − | |||
* Index of Aβ42:P-tau ratio (y) and T-tau (x) | * Index of Aβ42:P-tau ratio (y) and T-tau (x) | ||
| − | ** Sensitivity: 83% | + | ** Sensitivity: 83%; Specificity: 72%; Positive likelihood ratio: 3.0; Negative likelihood ratio: 0.24 |
| − | |||
| − | |||
| − | |||
* As patients become older, the presence of brain amyloid becomes more common and less specific to Alzheimer disease. Thus, it makes sense to get as a helpful diagnostic tool in patients that are in their 50’s or 60’s, but less so in their 70’s and 80’s. | * As patients become older, the presence of brain amyloid becomes more common and less specific to Alzheimer disease. Thus, it makes sense to get as a helpful diagnostic tool in patients that are in their 50’s or 60’s, but less so in their 70’s and 80’s. | ||
| − | * CSF studies in EOAD is similar to late-onset AD | + | * CSF studies in EOAD is similar to late-onset AD (Mendez 2019) |
| − | ** Tau/p-tau levels among phenotypic variants, particularly PCA, may be lower | + | ** Tau/p-tau levels among phenotypic variants, particularly PCA, may be lower (Mendez 2019) |
| − | * FTD has no validated biomarkers (though presence of AD pattern may help rule out FTD, as it would be an exclusion criteria for FTD) | + | * FTD has no validated biomarkers (though presence of AD pattern may help rule out FTD, as it would be an exclusion criteria for FTD) (Finger 2016) |
'''Autoimmune encephalitis''' | '''Autoimmune encephalitis''' | ||
| − | Importance of CSF vs serum testing: | + | Importance of CSF vs serum testing: (Graus et al, 2016) |
* most patients with autoimmune encephalitis have CSF antibodies and relevant antibodies might be found only in CSF | * most patients with autoimmune encephalitis have CSF antibodies and relevant antibodies might be found only in CSF | ||
* the repertoire of antibodies in the CSF and serum can be different in the same patient, and generally the CSF antibodies are more determinant of the clinical picture | * the repertoire of antibodies in the CSF and serum can be different in the same patient, and generally the CSF antibodies are more determinant of the clinical picture | ||
| Line 41: | Line 29: | ||
== References == | == References == | ||
| + | |||
| + | Finger, E. C. Frontotemporal Dementias. Contin. Minneap. Minn 22, 464–489 (2016). https://pubmed.ncbi.nlm.nih.gov/27042904/ | ||
| + | |||
| + | Graus, F. et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 15, 391–404 (2016) https://pubmed.ncbi.nlm.nih.gov/26906964/ | ||
| + | |||
| + | Mattsson, N. CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment. JAMA 302, 385 (2009). https://pubmed.ncbi.nlm.nih.gov/19622817/ | ||
| + | |||
| + | Mendez, M. F. Early-onset Alzheimer Disease and Its Variants: Contin. Lifelong Learn. Neurol. 25, 34–51 (2019). https://pubmed.ncbi.nlm.nih.gov/30707186/ | ||
Latest revision as of 09:30, 13 June 2021
Dementia
CSF biomarkers for Alzheimer’s disease demonstrate characteristic low amyloid-β1-42 (Aβ42) and high total and phosphorylated tau (p-tau) levels (Mattsson et al, 2009)
When predicting if MCI would develop incipient AD: (Mattsson et al, 2009)
- Aβ42 ≤482ng/L
- Sensitivity: 79%; Specificity: 65%; Positive likelihood ratio: 2.3; Negative likelihood ratio: 0.32
- T-tau ≥320ng/L
- Sensitivity: 86%; Specificity: 56%; Positive likelihood ratio: 1.9; Negative likelihood ratio: 0.26
- P-tau ≥52ng/L
- Sensitivity: 84%; Specificity: 47%; Positive likelihood ratio: 1.6; Negative likelihood ratio: 0.34
- Index of Aβ42:P-tau ratio (y) and T-tau (x)
- Sensitivity: 83%; Specificity: 72%; Positive likelihood ratio: 3.0; Negative likelihood ratio: 0.24
- As patients become older, the presence of brain amyloid becomes more common and less specific to Alzheimer disease. Thus, it makes sense to get as a helpful diagnostic tool in patients that are in their 50’s or 60’s, but less so in their 70’s and 80’s.
- CSF studies in EOAD is similar to late-onset AD (Mendez 2019)
- Tau/p-tau levels among phenotypic variants, particularly PCA, may be lower (Mendez 2019)
- FTD has no validated biomarkers (though presence of AD pattern may help rule out FTD, as it would be an exclusion criteria for FTD) (Finger 2016)
Autoimmune encephalitis
Importance of CSF vs serum testing: (Graus et al, 2016)
- most patients with autoimmune encephalitis have CSF antibodies and relevant antibodies might be found only in CSF
- the repertoire of antibodies in the CSF and serum can be different in the same patient, and generally the CSF antibodies are more determinant of the clinical picture
- concentration of CSF antibodies may correlate better with clinical course
- neuronal antibody testing using serum / cell-based assays can lead to false positives / negatives, which rarely happens in CSF testing
References
Finger, E. C. Frontotemporal Dementias. Contin. Minneap. Minn 22, 464–489 (2016). https://pubmed.ncbi.nlm.nih.gov/27042904/
Graus, F. et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 15, 391–404 (2016) https://pubmed.ncbi.nlm.nih.gov/26906964/
Mattsson, N. CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment. JAMA 302, 385 (2009). https://pubmed.ncbi.nlm.nih.gov/19622817/
Mendez, M. F. Early-onset Alzheimer Disease and Its Variants: Contin. Lifelong Learn. Neurol. 25, 34–51 (2019). https://pubmed.ncbi.nlm.nih.gov/30707186/
